In relapsing multiple sclerosis (MS) trials, the key objective centers around diminishing the annualized relapse rate (ARR).
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045
Home News Redefining Relapse in Efficacy Measures for Multiple Sclerosis Treatments: Stephen Krieger, MD; Enrique Alvarez, MD, PhD back to News
minute read
In relapsing multiple sclerosis (MS) trials, the key objective centers around diminishing the annualized relapse rate (ARR).
Topics: Press Coverage
13001 East 17th Place
Aurora, CO 80045
303.724.5375
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.